Suppr超能文献

[甲状腺相关眼病诊断和治疗中国专家共识(2022年版)]

[Chinese guideline on the diagnosis and treatment of thyroid-associated ophthalmopathy (2022)].

出版信息

Zhonghua Yan Ke Za Zhi. 2022 Sep 11;58(9):646-668. doi: 10.3760/cma.j.cn112142-20220421-00201.

Abstract

Thyroid-associated ophthalmopathy (TAO) is an orbital disease closely related to thyroid diseases. TAO has a prolonged course and possibility of blindness and disability. Its diagnosis and treatment can be complex with multiple disciplines involved. To improve the standardized diagnosis and treatment of TAO in China, the Oculoplastic and Orbital Disease Group of Chinese Ophthalmological Society of Chinese Medical Association and the Thyroid Group of Chinese Society of Endocrinology of Chinese Medical Association have jointly drawn up this first clinical guideline in China for TAO by complying with the principles, methods and steps of guideline formation. In this guideline, there are 24 recommendations for the major clinical problems in the diagnosis and treatment of TAO, including the clinical diagnostic criteria, disease staging and grading methods, novel treatment based on the pathogenesis, multi-disciplinary treatment, risk factor control, individualized selection of treatment such as drugs, radiation and surgery, therapeutic efficacy evaluation and critical illness management. This guideline provides instructions for clinicians to carry out relevant clinical and research work.

摘要

甲状腺相关性眼病(TAO)是一种与甲状腺疾病密切相关的眼眶疾病。TAO病程迁延,有致盲和致残的可能。其诊断和治疗可能涉及多个学科,较为复杂。为提高我国TAO的规范化诊断和治疗水平,中华医学会眼科学分会眼整形眼眶病学组和中华医学会内分泌学分会甲状腺学组遵循指南制定的原则、方法和步骤,联合制定了我国首部TAO临床指南。本指南针对TAO诊断和治疗中的主要临床问题提出了24条推荐意见,内容涵盖临床诊断标准、疾病分期和分级方法、基于发病机制的新型治疗、多学科治疗、危险因素控制、药物、放疗和手术等治疗方式的个体化选择、治疗疗效评估以及危重症管理等。本指南为临床医师开展相关临床和研究工作提供了指导。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验